A PHASE II STUDY OF TELISOTUZUMAB VEDOTIN IN PATIENTS WITH c-MET POSITIVE STAGE IV OR RECURRENT SQUAMOUS CELL LUNG CANCER (LUNG-MAP SUB-STUDY S1400K, NCT03574753)

INTRODUCTION: Lung-MAP S1400K was designed to evaluate the response to telisotuzumab vedotin, an antibody-drug conjugate targeting c-MET, in patients with c-MET positive squamous cell carcinoma (SCC). METHODS: Patients with previously treated SCC with c-MET positive tumors (H score ≥150, Ventana SP4...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Lung Cancer
Hlavní autoři: Waqar, Saiama N, Redman, Mary W, Arnold, Susanne M, Hirsch, Fred R, Mack, Philip C, Schwartz, Lawrence H, Gandara, David R, Stinchcombe, Thomas E, Leighl, Natasha B, Ramalingam, Suresh S, Tanna, Saloni H, Raddin, Ryan S, Minichiello, Katherine, Bradley, Jeffrey D, Kelly, Karen, Herbst, Roy S, Papadimitrakopoulou, Vassiliki A
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8044254/
https://ncbi.nlm.nih.gov/pubmed/33221175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2020.09.013
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky